Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Lymphoblastic Leukemia
St. Jude Discovery Offers New Avenues to Understanding an Aggressive Form of Leukemia
May 4th, 2008
Researchers at St. Jude Children's Research Hospital have discovered evidence that a series of genetic mutations work together to initiate most cases of an aggressive and often-fatal form of acute lymphoblastic leukemia (ALL). These defects, known as "cooperating oncogenic lesions," include the deletion of a gene, IKZF1, whose protein, Ikaros, normally helps guide the development of a blood stem cell into a lymphocyte. The researchers also found that loss of the same gene accompanied the transformation of chronic myelogenous leukemias (CMLs) to a life-threatening acute stage. "These findings provide new avenues to pursue to gain a better...
Source: Pharma Investments, Ventures & Law Weekly (2008-05-04)
|
